Get startedLog in
    Picture of POINT Biopharma Global logo

    PNT — POINT Biopharma Global News Story

    0.000.00%
    us flag iconLast trade - 00:00
    HealthcareSpeculativeMid Cap
    All News

    Brief: Lantheus And Point Biopharma Announce FDA Grants Fast Track Designation For Lu-Pnt2002

    Picture of POINT Biopharma Global logoPOINT Biopharma Global
    24/04/2023 12:42
    April 24 (Reuters) - Lantheus Holdings Inc  LNTH.O :
    * LANTHEUS AND POINT BIOPHARMA ANNOUNCE FDA GRANTS FAST
TRACK
DESIGNATION FOR ¹⁷⁷LU-PNT2002 FOR THE TREATMENT OF METASTATIC
CASTRATION RESISTANT PROSTATE CANCER
    * POINT BIOPHARMA GLOBAL INC - ENROLLMENT IN TRIAL IS
COMPLETE AND
SPLASH TOP LINE DATA IS EXPECTED IN SECOND HALF OF 2023

Source text for Eikon:  ID:nGNXbL1KrR 
Further company coverage:  LNTH.O 

 ((Reuters.Briefs@thomsonreuters.com;))

    Recent news on POINT Biopharma Global

    See all news